Amylyx Pharmaceuticals
The Director, Intellectual Property will develop and execute strategies to build durable IP protections for the company's molecules and programs, supporting the growth of the IP function. This role involves leading patent portfolio development, managing litigation readiness, and advising on trademark and IP-related contractual matters. The position requires strong expertise in patent enforcement of therapeutics and end-to-end experience in patent matters from early R&D to post-approval dispute resolution.
Headquarters
Cambridge, Massachusetts, United States
Company Size
201-500 employees
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for diseases with high unmet needs, including Post-Bariatric Hypoglycemia (PBH), Wolfram Syndrome, and Amyotrophic Lateral Sclerosis (ALS). Its lead program, Avexitide, is being evaluated in the pivotal Phase 3 LUCIDITY clinical trial for PBH. Amylyx advances its pipeline using rigorous science, well-defined mechanistic rationale, and a strong commitment to the patient communities it serves.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Amylyx Pharmaceuticals.
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating
4 days ago